Please find the enclosed intimation of the Company as per the captioned subject for your reference.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India reported total revenue of INR 22,755.8 Mn for FY 2025-26, marking a strong 33% year-on-year growth driven by Oncology (INR 16,100.9 Mn), Biopharmaceuticals (INR 5,243.2 Mn), and Rare Disease (INR 214.6 Mn). Profit after tax stood at INR 1,875.2 Mn for the full year, with Q4 profit at INR 448.8 Mn. The company secured 11 regulatory approvals during the year, including new indications for key drugs like Durvalumab, Osimertinib, Eculizumab, and Trastuzumab deruxtecan, significantly expanding its portfolio across oncology, rare diseases, and hyperkalaemia. CFO Bhavana Agrawal and MD Praveen Rao Akkinepally highlighted science-led innovation and disciplined execution as key growth drivers.
Sustained 33% revenue growth and 11 regulatory approvals signal strong commercial momentum and pipeline depth, which is positive for long-term shareholders despite the stock already reflecting high-growth pharma valuations.